Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jul 18, 2014

INFOGRAPHIC: Where Are The Biosimilars Hotspots?

A new graphic from research organization Decision Resources Group illustrates countries with biosimilars pathways, biosimilars in clinical trials, and regions with marketed biosimilars.

INFOGRAPHIC: Where Are The Biosimilars Hotspots?

  • The key data points of the above infographic from Decision Resources Group include:

    • >280 biosimilars in the pipeline
    • 17 biosimilar products approved ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »